Fig. 6 | Scientific Reports

Fig. 6

From: A multiparametric screen uncovers FDA-approved small molecules that potentiate the nuclear mechano-dysfunctions in ATR-defective cells

Fig. 6

Effects of combined treatments with AZD6738 on NE invaginations and MN in the TNBC cell line HCC1937. Combined treatments are reported in red, while single treatments are in pink. Data are reported as mean ± SD of three independent experiments with at least 3 technical replicates for the treated samples and at least 9 technical replicates for the DMSO conditions in each experiment. All the compounds were tested at 10 μM, except PF-477736 and Dasatinib tested at 1 μM and 0.1 μM respectively. AZD6738 was tested at 3 μM. Doses were selected considering those that impact nuclear morphology without inducing a reduction in the nuclei count greater than 35%. The effect of the compounds on NE invaginations (a) or micronuclei (b) is shown in the bar graphs. Statistical analysis by ordinary one-way ANOVA test using Bonferroni’s correction for multiple comparisons was applied, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.

Back to article page